A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2019
Price : $35 *
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 02 May 2019 Planned End Date changed from 13 Aug 2020 to 22 Jun 2020.
- 02 May 2019 Planned primary completion date changed from 13 Aug 2020 to 22 Jun 2020.
- 04 Apr 2019 Planned primary completion date changed from 24 Mar 2019 to 13 Aug 2020.